美國聯合醫療 UTHR 深 滬
等待開盤 09-20 09:30:00 美东时间
351.33
+8.740
+2.55%
華盛通- 最 高353.04
- 今 開345.46
- 成交量 45.44万股
- 最 低 344.47
- 昨 收 342.59
- 總市值 164.89亿
- 52周最高 366.08
- 市盈率 靜 17.73
- 換手率 0.97%
- 52周最低 208.6249
- 委 比 -44.34%
- 總股本 4693.26万
- 歷史最高 366.08
- 量 比 1.17
- 振 幅 2.50%
- 歷史最低 36.55
- 每 手 1
- 風險率 45.48%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多快讯 | liquidia公司：美国联合医疗在针对FDA的诉讼中提交了新的反诉，重新提出对FDA接受公司Yutrepia新药申请的挑战
Liquidia Corp: United Therapeutics Filed New Cross-Claims in FDA Suit Against F...
09-18 05:17
Is United Therapeutics Corporation's (NASDAQ:UTHR) Recent Stock Performance Tethered To Its Strong Fundamentals?
United Therapeutics' (NASDAQ:UTHR) stock is up by a considerable 20% over the p...
09-12 22:24
Keros gains after trial update on lung disorder therapy
Keros Therapeutics (NASDAQ:KROS) traded higher on Tuesday after announcing that it has closed screening in its Phase 2 TROPOS trial for its lung disorder therapy cibotercept (KER-012). The global plac...
09-04 03:29
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
08-28 21:16
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
In the ever-evolving and intensely competitive business landscape, conducting a...
08-27 23:00
Liquidia challenges exclusivity blocking Yutrepia in new lawsuit
Liquidia Corporation (NASDAQ:LQDA) announced Thursday a lawsuit challenging the recent FDA decision to grant a three-year exclusivity to Tyvaso DPI from United Therapeutics (UTHR), which it said had d...
08-22 20:39
快讯 | United Therapeutics Corp: Leerink Partners将目标价从$350上调至$375
United Therapeutics Corp : Leerink Partners Raises Target Price to $375 From $3...
08-21 18:18
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts
In the last three months, 8 analysts have published ratings on United Therapeut...
08-21 01:00
Wells Fargo Maintains Overweight on United Therapeutics, Raises Price Target to $380
Wells Fargo analyst Tiago Fauth maintains United Therapeutics (NASDAQ:UTHR) with a Overweight and raises the price target from $350 to $380.
08-21 00:21
These Analysts Cut Their Forecasts On Liquidia
Liquidia Corporation (NASDAQ:LQDA), on Monday, announced that the Food and Drug...
08-20 20:15
